Sign in to fuzzto save your conversations, follow your research and come back anytime.
Krishna Institute of Medical Sciences
SectorHealthcare
Krishna Institute of Medical Sciences Limited (KIMS) is an Indian healthcare company operating 12 multispecialty hospitals under the KIMS Hospitals brand. With over 4,000 beds, KIMS provides tertiary and quaternary healthcare services across more than 40 specialties and super specialties. The company's network includes hospitals in Telangana, Andhra Pradesh, and Maharashtra. KIMS offers medical education programs through affiliations with state medical boards and universities. The company's hospitals are equipped with advanced medical technology, including robotic surgical systems and specialized imaging equipment. KIMS has received various accreditations and awards for its healthcare services and facilities. In recent developments, Sunshine Hospitals became a subsidiary of KIMS in 2022, and the company opened a new gastroenterology unit in Vizag.
In the news
KIMS signs ₹183-bed hospital O&M deal in Andhra Pradesh
Investec sets ₹1,000 target for KIMS stock with 32.7% upside
KIMS to operate 250-bed Hyderabad hospital under 5-year deal
KIMS Issues 77.02 Lakh Convertible Warrants for ₹150 Crore Funding
KIMS Q1 profit drops 47% despite strong volume growth
5 Stocks Dominate India's Top Smallcap Funds with ₹8,000 Cr Holdings
Top stocks to watch: Wipro, HDFC Bank, Power Grid today
Corporate Developments: Dr Reddy's, Adani Green, JSW Energy, KIMS, Nestlé, NLC India, LIC
Four Pharma Stocks in Focus: Licensing Deals & Fund Raises
KIMS approves ₹599.99 cr warrant issue to promoters at ₹779/warrant
KIMS gains 1.31% as board mulls fundraising plan on June 13
5 Stocks to Buy: KIMS, Endurance, Kalpataru, Godfrey Phillips
Regional Hospital Stocks Show Mixed Q1 2026 Results Amid Growth
KIMS Stock Breaks Triangle Pattern, Targets ₹900-920
KIMS board approves ₹1,500 crore equity fundraise
The Quarter story
The two most recent quarterly results, compared side-by-side.
Revenue and bed capacity are expanding rapidly, but profitability and margins are under pressure from aggressive growth and rising operational costs.
Total revenue grows from ₹878.7 Cr in Q1 FY26 to ₹11,959 Cr in Q1 FY27, driven by steady patient volume increases.
PAT margin compresses from 9.7% in Q1 FY26 to 3.1% in Q1 FY27, as expansion costs outpace profit growth.
Bed capacity expands from 5,499 to 7,459 over five quarters, adding nearly 2,000 new beds to the network.
Basic EPS halves from ₹2.0 to ₹1.04 over five quarters, reflecting diluted earnings per share.
Average revenue per patient rises from ₹1,53,094 to ₹1,63,573 from Q1 FY26 to Q1 FY27, showing consistent pricing power.
Telangana occupancy drops from 56.2% to 41.1% in Q1 FY27, as new beds take time to fill.
Kerala occupancy climbs from 34.2% to 46.0% over the period, while EBITDA margin turns positive at 9.7% after starting at -6.9%.
Consolidated EBITDA swings from ₹199.7 Cr to -₹50.8 Cr over the period, weighed down by lease expenses and new facility ramp-up costs.
Average length of stay falls from 3.56 to 3.47 days across five quarters, indicating faster patient discharge and better bed turnover.
Company insights, generated from the most recent coverage.
Promoter equity pledge disclosed on Sep 22, 2026 under SEBI SAST adds a governance overhang just as the stock breaks down — reduces confidence in downside support from the promoter.
A 16% markup cap would bite hardest at Kondapur, Thane and Bengaluru Mahadevapura — units still at or below breakeven have no margin cushion to absorb a pharmacy revenue haircut.
KIMS fell 5.65% to ₹726.40 on Sep 30 on 1.34x average volume — heavier volume than the earlier thin-volume slide confirms genuine distribution, not just drift.